2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane | 116673-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
• CAS: 116673-47-3
• 化学式: C₂₁H₂₆O₈
• 分子量: 406.4
• InChiKey: DUAYHYGJMLZLCE-UHFFFAOYSA-N

物化性质

• 沸点：
  508.3±50.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  73.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3,4,5-三甲氧基苯甲醛 、 1-(3,4,5-三甲氧基苯基)乙烷-1,2-二醇 生成 2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
  参考文献：
  名称：

  COREY, E. J.;CHEN, CHUNG-PIN;PARRY, M. J., TETRAHEDRON LETT., 29,(1988) N 24, C. 2899-2902

  摘要：

  DOI：

文献信息

• Method for controlling the plasma level of lipoproteins
  申请人：NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO

  公开号：EP0875247A1

  公开（公告）日：1998-11-04

  A compound which is an antagonist of platelet activating factor (PAF-antagonist) or a structurally related compound thereof not having PAF-antagonistic activity can be used for decreasing the plasma level of lipoprotein(a) and/or increasing the plasma level of high-density lipoprotein. The compound may be an azepine derivative, especially a benzo- or thienotriazolo-diazepine derivative, a diphenyl-tetrahydrofuran or diphenyldioxolane derivative or a tetrahydrofuran phospholipid analogue.

  血小板活化因子拮抗剂（PAF-antagonist）化合物或其结构相关的不具有 PAF 拮抗活性的化合物可用于降低血浆中脂蛋白（a）的水平和/或提高血浆中高密度脂蛋白的水平。该化合物可以是氮杂卓衍生物，特别是苯并三唑或噻吩三唑-二氮杂卓衍生物、二苯基四氢呋喃或二苯基二氧戊环衍生物或四氢呋喃磷脂类似物。
• METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES
  申请人：——

  公开号：US20030190368A1

  公开（公告）日：2003-10-09

  Diagnostic methods that rely on the use of one or more assays that assess cellular activation are provided. The assays are performed on whole blood or leukocytes, and indicate individually or in combination the level of cardiovascular cell activation, which is pivotal in many chronic and acute disease states. These results of the assays are used within a clinical framework to support therapeutic decisions such as: further testing for infectious agents, anti-oxidant or anti-adhesion therapy, postponement and optimal re-scheduling of high-risk surgeries, classifying susceptibility to and progression rates of chronic disease such as diabetes, atherogenesis, and venous insufficiency; extreme interventions in trauma cases of particularly high risk and activation-lowering therapies. Also provided is as composition derived from a pancreatic homogenate that contains circulating cell activating factors, which can serve as targets for drug screening to identify drug candidates for use in activation lowering therapies. Methods for lowering cell activation by administering protease inhibitors, particularly serine protease inhibitors, are also provided.

  提供的诊断方法依赖于使用一种或多种评估细胞活化的检测方法。这些检测在全血或白细胞上进行，可单独或联合显示心血管细胞活化的水平，这在许多慢性和急性疾病状态中至关重要。这些检测结果可在临床框架内用于支持治疗决策，例如：进一步检测感染性病原体、抗氧化或抗粘连疗法、推迟和优化高风险手术的重新安排、对糖尿病、动脉粥样硬化和静脉功能不全等慢性疾病的易感性和进展率进行分类；对风险特别高的创伤病例进行极端干预，以及降低活化水平的疗法。此外，还提供了一种从胰腺匀浆中提取的组合物，该组合物含有循环细胞活化因子，可作为药物筛选的靶点，以确定用于降低活化疗法的候选药物。还提供了通过施用蛋白酶抑制剂，特别是丝氨酸蛋白酶抑制剂来降低细胞活化的方法。
• Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
  申请人：——

  公开号：US20040028756A1

  公开（公告）日：2004-02-12

  Antagonists to platelet-activating factor provide analgesic effects as well as limit the release of inflammatory mediators. Use of these antagonists in the form of pharmaceutical compositions or nutritionals is beneficial (1) in the treatment of acute and/or chronic pain; (2) in the inhibition of inappropriate or excessive contraction of the uterus; (3) in the treatment of septic shock; and (4) in the inhibition of angiogenesis and/or tumor cell proliferation.

  血小板活化因子拮抗剂具有镇痛效果，并能限制炎症介质的释放。以药物组合物或营养品的形式使用这些拮抗剂有利于：(1) 治疗急性和/或慢性疼痛；(2) 抑制子宫不适当或过度收缩；(3) 治疗脓毒性休克；以及 (4) 抑制血管生成和/或肿瘤细胞增殖。
• Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
  申请人：Wurtman J. Richard

  公开号：US20050032713A1

  公开（公告）日：2005-02-10

  Antagonists to platelet-activating factor provide analgesic effects as well as limit the release of inflammatory mediators. Use of these antagonists in the form of pharmaceutical compositions or nutritionals is beneficial (1) in the treatment of acute and/or chronic pain; (2) in the inhibition of inappropriate or excessive contraction of the uterus; (3) in the treatment of septic shock; and (4) in the inhibition of angiogenesis and/or tumor cell proliferation.

  血小板活化因子拮抗剂具有镇痛效果，并能限制炎症介质的释放。以药物组合物或营养品的形式使用这些拮抗剂有利于：(1) 治疗急性和/或慢性疼痛；(2) 抑制子宫不适当或过度收缩；(3) 治疗脓毒性休克；以及 (4) 抑制血管生成和/或肿瘤细胞增殖。
• COREY, E. J.;CHEN, CHUNG-PIN;PARRY, M. J., TETRAHEDRON LETT., 29,(1988) N 24, C. 2899-2902
  作者：COREY, E. J.、CHEN, CHUNG-PIN、PARRY, M. J.

  DOI：——

  日期：——